Manufacturing Resilience in Europe - Availability of Medicine and Vaccines
Since the outbreak of the COVID-19 pandemic, it has become clear that public health is an area where more European cooperation is both desirable and necessary. Among political leaders throughout the European Union, willingness and awareness has grown to tackle long-standing issues, such as medicine shortages.
Since the outbreak of the COVID-19 pandemic, it has become clear that public health is an area where more European cooperation is both desirable and necessary. Among political leaders throughout the European Union, willingness and awareness has grown to tackle long-standing issues, such as medicine shortages.
In this light, the pharmaceutical strategy, published by the European Commission in November last year, could be considered as one of the next steps towards closer European cooperation on public health. One of the objectives of the Pharmaceutical Strategy is to improve affordability, access and availability of medicines in Europe. At the heart of this agenda is the diversification of the sources of supply for essential medicines and active pharmaceutical ingredients (APIs) and reinforcing the manufacturing capacity within the EU.
On top of the resilience of the manufacturing capacity, there is also a need to invest in and expand the innovation capacity of the European Union. Expertise and research, development and innovation are core strengths of European companies and should be kept at the heart of the industrial competitiveness of the EU.
With this webinar, Renew wish to put spotlight on the manufacturing resilience debate and the innovation capacity to support the implementation of the pharmaceutical strategy. The webinar will focus on access, development and availability of medicines and bringing concrete policy recommendations to move the agenda forward.
